Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures

NCT00275912 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00275912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
September 11, 2006
Completion date
September 28, 2007
Enrollment
60 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, partial seizures